CORRECTION: Herantis publishes 2H & FY 2022 Report
Correction to release sent on March 2[nd], 2023, at 8:00 a.m. EET: the release category has been updated by removal of “insider information” and the Key Figures table is now included in the release. Nothing else differs from the previous release. Herantis Pharma Plc Company Release, March 7, 2023, at 19:40 EET/ 18:40 CET “We made good progress in 2022 achieving encouraging preclinical results and submitting clinical trial application (CTA) for HER-096. The compelling preclinical data supports the potential of HER-096 to be a disease-modifying therapy for Parkinson’s disease with a